Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vaxart Inc VXRT

Healthcare Biotechnology
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its... see more

Recent & Breaking News (NDAQ:VXRT)

Vaxart Announces Pricing of Underwritten Public Offering

Business Wire April 9, 2019

Vaxart to Present at Global Medical Meetings in April

Business Wire March 28, 2019

Vaxart Completes Dosing of the Lead-In Cohort in Bivalent Norovirus Vaccine Phase 1b Clinical Trial

Business Wire March 27, 2019

Vaxart Announces Closing of Registered Direct Offering of Common Stock

Business Wire March 20, 2019

Thinking about buying stock in Aurora Cannabis Inc., China Bat Group Inc., Nevro Corp., Shineco Inc., or Vaxart Inc.?

PR Newswire March 20, 2019

Vaxart Announces $3 Million Registered Direct Offering Priced At-the-Market

Business Wire March 19, 2019

Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial

Business Wire March 19, 2019

Vaxart Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

Business Wire February 6, 2019

Vaxart to Present at World Vaccine and Immunotherapy Congress West Coast 2018

Business Wire November 28, 2018

Vaxart Announces Third Quarter 2018 Financial Results and Provides Corporate Update

Business Wire November 9, 2018

New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart’s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity

Business Wire October 4, 2018

Vaxart Announces Second Quarter 2018 Financial Results and Corporate Update

Business Wire August 9, 2018

Vaxart Announces Publication of the Phase 1 Results of its Oral Norovirus Tablet Vaccine in Journal of Clinical Investigation Insight

Business Wire July 12, 2018

Oral RSV Vaccine - Preclinical Data Published in Vaccine

Business Wire June 27, 2018

Vaxart Reports Topline Results from Phase 2 Trial of Teslexivir™ for the Treatment of Condyloma

Business Wire June 4, 2018

Vaxart to Present at the Jefferies 2018 Global Healthcare Conference

Business Wire June 1, 2018

Vaxart to Present at ASM Microbe 2018

Business Wire May 31, 2018

Vaxart Announces First Quarter 2018 Financial Results and Corporate Update

Business Wire May 15, 2018

Vaxart Appoints Dr. David Taylor as Chief Medical Officer

Business Wire May 1, 2018

Vaxart Announces $5 Million Inavir® Revenue Milestone

Business Wire April 20, 2018